Share

Huma Q. Rana

M.D., MPH

Clinical Director, Division of Cancer Genetics and Prevention

Senior Physician, Dana-Farber Cancer Institute

Assistant Professor of Medicine, Harvard Medical School

Huma Q. Rana, MD, MPH is the Clinical Director of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. At Dana-Farber and its affiliates and satellites, Dr. Rana oversees the medical management and the clinical operations that provide care to individuals with rare genetic susceptibilities to cancer. 

In addition to her clinical work, Dr. Rana leads multiple clinical research projects focused on developing cancer prevention and screening for those with hereditary cancer risk, and novel approaches to improving access to cancer genetics services. 

Dr. Rana received her medical degree from the Rutgers Robert Wood Johnson Medical School, completed her residencies in Internal Medicine and Clinical Genetics at the Icahn School of Medicine at Mount Sinai, and received her MPH from the Harvard T.H. Chan School of Public Health.  She has been a member of the Dana-Farber faculty since 2012.  

Huma Q. Rana

M.D., MPH

Clinical Director, Division of Cancer Genetics and Prevention

Senior Physician, Dana-Farber Cancer Institute

Assistant Professor of Medicine, Harvard Medical School

Huma Q. Rana, MD, MPH is the Clinical Director of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. At Dana-Farber and its affiliates and satellites, Dr. Rana oversees the medical management and the clinical operations that provide care to individuals with rare genetic susceptibilities to cancer. 

In addition to her clinical work, Dr. Rana leads multiple clinical research projects focused on developing cancer prevention and screening for those with hereditary cancer risk, and novel approaches to improving access to cancer genetics services. 

Dr. Rana received her medical degree from the Rutgers Robert Wood Johnson Medical School, completed her residencies in Internal Medicine and Clinical Genetics at the Icahn School of Medicine at Mount Sinai, and received her MPH from the Harvard T.H. Chan School of Public Health.  She has been a member of the Dana-Farber faculty since 2012.  

Recent Publications

Concurrent Pathogenic Variants of BRCA1, MUTYH and CHEK2 in a Hereditary Cancer Family

Published On 2022 Nov 11

Journal article

Concurrent pathogenic variants (PVs) in cancer predisposition genes have been reported in 0.1-2% of hereditary cancer (HC) patients. Determining concurrent PVs is crucial for the diagnosis, treatment, and risk assessment of unaffected family members. Next generation sequencing based diagnostic tests, which are widely used in HCs, enable the evaluation of multiple genes in parallel. We have screened the family members of a patient with bilateral breast cancer who was found to have concurrent PVs...


Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2

Published On 2022 Sep 22

Journal article

CONCLUSIONS AND RELEVANCE: CHEK2 PVs, with few exceptions (p.I157T, p.S428F, and p.T476M), were associated with similar cancer phenotypes irrespective of variant type. CHEK2 PVs were not associated with colorectal cancer, but were associated with breast, kidney, and thyroid cancers. Compared with other CHEK2 PVs, the frequent p.I157T, p.S428F, and p.T476M alleles have an attenuated association with breast cancer and were not associated with nonbreast cancers. These data may inform the genetic...